CNS PHARMACEUTICALS INC (CNSP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.01-7.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CNSP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CNSP — officer change
Dated 2026-10-02
The provided text is only the standard Item 5.02 header and introductory phrase, containing no specific details about a person, role, or action to classify.
Why it matters: CNSP's new plan depends on buying a clinical-stage asset. A named deal would show that the search has led to action.
Supportive ifA company filing names an acquired or licensed cancer or neurology asset. It gives the deal terms.
Worry ifThe next quarterly report says no asset deal has closed, or the search has been paused.
Why it matters: CNSP is loss-making, and the May financing is meant to fund its asset search. The report can show how much cash remains for that plan.
Watch forThe November 13 report shows cash above the June 30 level of $22.5 million in new financing proceeds, with no new share sale.
Also watch forThe report shows cash below the June 30 level of $22.5 million in new financing proceeds. Or it shows a new share sale to fund operations.
Why it matters: The filing text does not name the officer or describe the change. Those details could clarify whether the new team remains in place.
Watch forA filing names the officer. It confirms the change does not affect the CEO, CFO, CTO, CMO, or CBO roles listed in the June presentation.
Also watch forA filing names a departure or replacement in one of those five roles.
Why it matters: Management aims to reach a clinical or regulatory milestone within a year of buying an asset. Hitting one would show the plan is moving forward.
Supportive ifWithin 12 months after an asset deal, CNSP reports a named clinical or regulatory milestone. This could be a trial start or FDA decision.
Worry ifNo clinical or regulatory milestone is reported by the end of the 12-month period. Or the company delays the stated milestone.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$287 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $927 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,266 loss on $10,000 · 72.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A deal could help fund CNSP's new plan without raising more shares. No deal would leave the legacy program without this source of funds.
Supportive ifCNSP announces a signed deal to license berubicin. It names an upfront payment, milestones, or royalties.
Worry ifThe next quarterly report says no berubicin license deal has been signed, or CNSP stops seeking one.